CMS Proposes Rules for Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services (CMS) is proposing a new rule to put existing guidance into formal regulations. This action codifies policies for the Medicare Drug Price Negotiation Program, which allows the government to negotiate prices for certain high-cost drugs. It also updates rules for the Medicare Prescription Drug Benefit Program under Part D.

Why it matters: This is primarily an administrative update that turns temporary guidance into permanent regulation. While it does not change the core structure of the negotiation program, it provides clearer rules for drug manufacturers and pharmacy benefit managers on how to comply with specific technical requirements. The practical impact is limited to those involved in the 2029 pricing cycle and beyond.

Who it affects

• Pharmaceutical manufacturers subject to Medicare drug price negotiations

---

This proposed rule comes from the Centers for Medicare & Medicaid Services within the Department of Health and Human Services, published in the Federal Register. Readers should check the original document for full legal text before relying on this summary.

Agency: Health and Human Services Department, Centers for Medicare & Medicaid Services
Source: Federal Register — read the official document